Vascular Ehlers-Danlos Syndrome (vEDS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Vascular Ehlers-Danlos Syndrome (vEDS) is an autosomal dominant condition; a child only has to inherit a defect in the COL3A1 gene from one parent to have the disorder. About half of people with vascular Ehlers-Danlos syndrome inherited the COL3A1 mutation from an affected parent. The other half of people with the condition have a spontaneous disease-causing mutation; that is, they are the first person in their family to have vascular Ehlers-Danlos syndrome. Each child of an affected parent has a 50% chance of inheriting the mutation and developing the disorder. The diagnosis of vascular Ehlers-Danlos syndrome is based on examining and identifying certain features and confirmation by laboratory testing. This testing may include DNA sequence analysis, deletion/duplication analysis, and biochemical (protein-based) testing. Genetic testing detects 98 percent of the changes in the gene for vascular Ehlers-Danlos syndrome; the rest require more specialized tests. Genetic testing is strongly recommended to confirm the vascular Ehlers-Danlos syndrome diagnosis when a person has a combination of any two of the major features of the condition, such as; Arterial rupture, Intestinal rupture, Uterine rupture during pregnancy, and Family history of vascular Ehlers-Danlos syndrome.

·       In the United States, the Vascular Ehlers-Danlos Syndrome (vEDS) prevalence rate is varied between 1 to 2 cases per 200,000 population.

 

Thelansis’s “Vascular Ehlers-Danlos Syndrome (vEDS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Vascular Ehlers-Danlos Syndrome (vEDS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Vascular Ehlers-Danlos Syndrome (vEDS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Vascular Ehlers-Danlos Syndrome (vEDS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Vascular Ehlers-Danlos Syndrome (vEDS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Vascular Ehlers-Danlos Syndrome (vEDS), Vascular Ehlers-Danlos Syndrome (vEDS) market outlook, Vascular Ehlers-Danlos Syndrome (vEDS) competitive landscape, Vascular Ehlers-Danlos Syndrome (vEDS) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)